Drug
ELND005
ELND005 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
completed375%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
NCT01791725
completedphase_2
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
NCT00568776
completedphase_2
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
NCT01735630
terminatedphase_2
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder
NCT01674010
Clinical Trials (4)
Showing 4 of 4 trials
NCT01791725Phase 2
A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
NCT00568776Phase 2
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
NCT01735630Phase 2
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
NCT01674010Phase 2
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4